Sino Biopharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Sino Biopharmaceutical Stock Forecast and Price Target
Sino Biopharmaceutical has an average price target of HK$4.02 recently offered by notable experts for 2024, which would represent a potential upside of approximately 71.79% from the last closing price in April, 2024 if reached. This potential increase is based on a high estimate of HK$8.46 and a low estimate of HK$2.81. If you're looking for information on Sino Biopharmaceutical stock, consider checking out the forecasts for comparable firms such as SEHK:1112.
71.79% Upside
Sino Biopharmaceutical Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Sino Biopharmaceutical has seen a decline in its Price, from HK$4.82 to HK$0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach HK$5.10 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Sino Biopharmaceutical will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 43 Stock Forecast | C.P. Pokphand | - |
17
|
HK$1.14 | Buy/Sell | HK$0.12 | -100.00% |
| 867 Stock Forecast | China Medical System Holdings | Outperform |
18
|
HK$7.00 | Buy/Sell | HK$16.53 | 59.57% |
| HCM Stock Forecast | HUTCHMED (China) | Buy |
4
|
£2.70 | Buy/Sell | £5.40 | 83.33% |
| 3933 Stock Forecast | The United Laboratories Intern... | Outperform |
18
|
HK$9.59 | Buy/Sell | HK$10.95 | 6.88% |
| 570 Stock Forecast | China Traditional Chinese Medi... | Buy |
16
|
HK$4.32 | Buy/Sell | HK$3.98 | -0.23% |
Sino Biopharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Revenue for Sino Biopharmaceutical has grown by 21.71%, going from HK$23.65B to HK$28.78B. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach HK$33.70B – an increase of 17.11%. Over the next seven years, experts anticipate that Revenue growth for Sino Biopharmaceutical will be 43.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 2005 Stock Forecast | SSY Group | Buy |
17
|
HK$4.71 | Buy/Sell | HK$5.99 | 29.51% |
| 512 Stock Forecast | Grand Pharmaceutical Group | Buy |
18
|
HK$3.97 | Buy/Sell | HK$7.60 | -100.00% |
| 1112 Stock Forecast | Health and Happiness (H&H) Int... | Buy |
16
|
HK$10.08 | Buy/Sell | HK$14.45 | 35.71% |
.jpg)
Sino Biopharmaceutical Dividend per Share Forecast for 2023 - 2025 - 2030
Sino Biopharmaceutical's Dividend per Share has grown in the last two years, jumping from HK$0.06 to HK$0.11 – an increase of 83.33%. For the next year, 16 analysts project Sino Biopharmaceutical's Dividend per Share to drop by 36.36%, reaching HK$0.07. By 2030, professionals believe that Sino Biopharmaceutical's Dividend per Share will decrease by 0.00%, reaching HK$0.11 – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 1230 Stock Forecast | Yashili International Holdings... | - |
11
|
HK$1.20 | Buy/Sell | HK$0.60 | -100.00% |
| 460 Stock Forecast | Sihuan Pharmaceutical Holdings... | Outperform |
16
|
HK$0.51 | Buy/Sell | HK$2.47 | -100.00% |
| 2327 Stock Forecast | Meilleure Health International... | - |
13
|
HK$0.12 | Buy/Sell | HK$1.10 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 950 Stock Forecast | Lee's Pharmaceutical Holdings | Sell |
16
|
HK$1.16 | Buy/Sell | HK$1.00 | -13.79% |
| 932 Stock Forecast | Shunten International (Holding... | - |
7
|
HK$0.05 | Buy/Sell | HK$0.00 | -100.00% |
| 239 Stock Forecast | Pak Fah Yeow International | - |
13
|
HK$2.05 | Buy/Sell | HK$0.00 | -100.00% |
Sino Biopharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Sino Biopharmaceutical's EBITDA has grown, increasing from HK$5.66B to HK$6.75B – an increase of 19.23%. For next year, the 18 analysts predict EBITDA of HK$7.83B, which would mean an increase of 16.05%. Over the next seven years, the pros' prediction is EBITDAof HK$14.31B, which would mean a seven-year growth forecast of 111.97%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 897 Stock Forecast | Wai Yuen Tong Medicine Holding... | - |
0
|
HK$0.24 | Buy/Sell | HK$0.00 | -100.00% |
| 455 Stock Forecast | Tianda Pharmaceuticals | - |
3
|
HK$0.19 | Buy/Sell | HK$0.00 | -100.00% |
| 1498 Stock Forecast | PuraPharm Corporation | - |
0
|
HK$0.85 | Buy/Sell | HK$1.50 | -100.00% |
Sino Biopharmaceutical EBIT Forecast for 2023 - 2025 - 2030
Sino Biopharmaceutical's EBIT has increased by 43.49% In the last two years, going from HK$4.10B to HK$5.88B. In the next year, analysts expect EBIT to reach HK$6.61B – an increase of 12.38%. For the next seven years, the forecast is for EBIT to grow by 51.86%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 8205 Stock Forecast | Shanghai Jiaoda Withub Informa... | - |
0
|
HK$0.20 | Buy/Sell | HK$0.00 | -100.00% |
| 858 Stock Forecast | Extrawell Pharmaceutical Holdi... | - |
0
|
HK$0.03 | Buy/Sell | HK$218.63 | -100.00% |
| 8120 Stock Forecast | China Demeter Financial Invest... | - |
2
|
HK$0.17 | Buy/Sell | HK$0.00 | -100.00% |
Sino Biopharmaceutical EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Sino Biopharmaceutical has seen a decline in its EPS, from HK$0.17 to HK$0.00 – a 100.00% decrease. In the coming year, analysts are expecting an increase in EPS, predicting it will reach HK$0.18 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Sino Biopharmaceutical will be 100.00%.
Site Navigation
.jpg)